{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anal+Neoplasm&page=4", "query": { "condition": "Anal Neoplasm", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 218, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anal+Neoplasm&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anal+Neoplasm&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T16:20:09.210Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05243966", "title": "Myriad™ Augmented Soft Tissue Reconstruction Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Abdominal Wound Dehiscence", "Necrotizing Soft Tissue Infection", "Lower Extremity Wound", "Pilonidal Sinus", "Anal Fistula", "Hidradenitis Suppurativa", "Pressure Injury" ], "interventions": [ { "name": "Myriad Matrix™ and Myriad Morcells™", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Aroa Biosurgery Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2022-01-10", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-22T16:20:09.210Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05243966" }, { "nct_id": "NCT04472429", "title": "Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Carcinoma of the Anal Canal" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "retifanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 308, "start_date": "2020-11-09", "completion_date": "2025-09-26", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-22T16:20:09.210Z", "location_count": 14, "location_summary": "Tucson, Arizona • Duarte, California • Sacramento, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04472429" }, { "nct_id": "NCT06233331", "title": "Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Papilloma Virus", "Human Immunodeficiency Virus", "Anal Intraepithelial Neoplasia", "High-Grade Squamous Intraepithelial Lesions" ], "interventions": [ { "name": "Dose Level 1 ACU-D1 ointment", "type": "DRUG" }, { "name": "Dose Level 2 ACU-D1 ointment", "type": "DRUG" }, { "name": "Dose Level 3 ACU-D1 ointment", "type": "DRUG" }, { "name": "Vulvar/ Perianal Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 9, "start_date": "2026-12", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-22T16:20:09.210Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06233331" }, { "nct_id": "NCT00316888", "title": "Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2007-02-28", "completion_date": "2021-08-17", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-10-22T16:20:09.210Z", "location_count": 125, "location_summary": "Stanford, California • Fort Collins, Colorado • Chicago, Illinois + 88 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00316888" }, { "nct_id": "NCT06263088", "title": "EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gastrointestinal Cancer", "Colon Cancer", "Rectal Cancer", "Anal Cancer", "Esophageal Cancer", "Stomach Cancer", "Appendix Cancer", "Pancreas Cancer", "Liver Cancer", "Neuroendocrine Tumors" ], "interventions": [ { "name": "EQUITY GI", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2024-12-01", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-22T16:20:09.210Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06263088" }, { "nct_id": "NCT07425054", "title": "ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Cancer", "HPV-Related Carcinoma", "Squamous Cell Carcinoma of the Anus" ], "interventions": [ { "name": "HPV ctDNA Response based radiation", "type": "RADIATION" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Jennifer Dorth", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2026-06-19", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-22T16:20:09.210Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07425054" }, { "nct_id": "NCT00394602", "title": "Chemoradiation-Induced Nausea and Emesis: Quality of Life", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gastric Cancer", "Pancreatic Cancer", "Cervical Cancer", "Vulvar Cancer", "Endometrial Cancer", "Anal Cancer" ], "interventions": [ { "name": "Interview", "type": "BEHAVIORAL" }, { "name": "Questionnaire", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 207, "start_date": "2004-04-07", "completion_date": "2019-05-08", "has_results": false, "last_update_posted_date": "2020-01-02", "last_synced_at": "2026-10-22T16:20:09.210Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00394602" }, { "nct_id": "NCT06669572", "title": "Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Squamous Cell", "Anorectal Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2025-07-11", "completion_date": "2029-03-26", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-22T16:20:09.210Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06669572" }, { "nct_id": "NCT00568425", "title": "QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anal Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "30 Years to 70 Years" }, "enrollment_count": 10, "start_date": "2005-09", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2020-06-29", "last_synced_at": "2026-10-22T16:20:09.210Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00568425" }, { "nct_id": "NCT03499795", "title": "VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Neoplasm" ], "interventions": [ { "name": "VGX-3100", "type": "BIOLOGICAL" }, { "name": "CELLECTRA™ 5PSP", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2018-05-15", "completion_date": "2021-05-26", "has_results": true, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-10-22T16:20:09.210Z", "location_count": 2, "location_summary": "Chicago, Illinois • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03499795" } ] }